AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of "Buy" by Brokerages

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has been given an average recommendation of "Buy" by the nine analysts that are presently covering the company, MarketBeat.com reports. Nine analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $49.44.

A number of research firms have commented on ATRC. Canaccord Genuity Group decreased their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research report on Friday. BTIG Research restated a "buy" rating on shares of AtriCure in a report on Thursday. Needham & Company LLC reiterated a "buy" rating and issued a $51.00 target price on shares of AtriCure in a report on Thursday. JMP Securities reissued a "market outperform" rating and issued a $60.00 target price on shares of AtriCure in a research report on Monday, February 10th. Finally, Stifel Nicolaus raised their price target on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares of the company's stock, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.20% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On AtriCure

A number of large investors have recently modified their holdings of ATRC. Adage Capital Partners GP L.L.C. acquired a new position in shares of AtriCure during the fourth quarter worth $9,168,000. Kennedy Capital Management LLC lifted its holdings in AtriCure by 29.8% during the 4th quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after buying an additional 172,648 shares during the last quarter. Marshall Wace LLP lifted its holdings in AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock worth $18,922,000 after buying an additional 167,476 shares during the last quarter. Oberweis Asset Management Inc. acquired a new position in shares of AtriCure during the 4th quarter worth about $4,630,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of AtriCure by 24.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after acquiring an additional 136,015 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Trading Down 7.4 %

Shares of AtriCure stock traded down $2.54 during trading hours on Tuesday, hitting $31.83. The company's stock had a trading volume of 538,818 shares, compared to its average volume of 674,762. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -33.50 and a beta of 1.53. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure has a twelve month low of $18.94 and a twelve month high of $43.11. The firm has a fifty day moving average of $38.10 and a 200-day moving average of $33.89.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.